首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1738670

2026 年至 2032 年癌症生物治疗市场（按治疗类型、癌症类型、最终用户和地区划分）

Cancer Biological Therapy Market By Type of Therapy (Monoclonal Antibodies, Cancer Vaccines), Cancer Type (Breast Cancer, Lung Cancer), End-User (Hospitals Cancer Treatment Centers), & Region for 2026-2032

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

癌症生物治疗市场评估-2026-2032

全球癌症发生率的上升推动了对创新治疗方案的需求，并刺激了癌症生物疗法的应用。个人化医疗（专注于根据个人基因特征量身订做治疗）的转变，正在推动市场规模在2024年突破937.4亿美元，到2032年估值将达到约1533.5亿美元。

除此之外，生物疗法的临床成功和患者预后的改善也刺激了癌症生物疗法的应用。政府对癌症研究和治疗的资金投入不断增加以及优惠政策的出台，推动市场在 2026 年至 2032 年期间以 7% 的复合年增长率增长。

癌症生物治疗市场定义/概述

癌症生物疗法，也称为生物疗法或免疫疗法，利用活体生物体、源自活体生物体的物质或此类物质的合成物来治疗癌症。这些治疗方法透过增强人体的天然防御能力来对抗癌症，或针对参与癌症生长和进展的特定分子。生物疗法的例子包括单株抗体、癌症疫苗和细胞疗法。

癌症生物疗法用于治疗各种类型的癌症，通常与化疗、放射线治疗和手术等其他疗法合併使用。它们尤其擅长针对特定癌细胞，同时最大限度地减少对健康细胞的损害。单株抗体可用于抑制癌细胞生长、标记癌细胞以便免疫系统摧毁，或直接将放射治疗或化疗输送至癌细胞。癌症疫苗旨在刺激免疫系统攻击癌细胞，而细胞疗法（例如 CAR-T 细胞疗法）则可改变患者自身的免疫细胞，使其更有效地攻击癌症。

全球癌症发生率的不断上升将如何导致癌症生物疗法的应用增加？

全球癌症发生率的上升是癌症生物治疗市场的主要驱动力。根据世界卫生组织 (WHO) 预测，到 2040 年，癌症患者数量将比 2020 年增加 60%。美国国家癌症研究所 (美国 National Cancer Institute) 的数据显示，约有 39.5% 的人会在一生中的某个阶段被诊断出癌症。癌症负担的加重导致对生物疗法等有效且有针对性的治疗的需求增加。为了因应这一趋势，默克公司于 2024 年 2 月宣布，将以新型查核点抑制剂为中心，扩展其免疫肿瘤学产品线。同样，罗氏公司于 2024 年 4 月宣布推出一款新的个人化癌症疫苗平台，该平台将 mRNA 技术与成熟的生物疗法相结合。

生物技术的进步和对癌症生物学的深入了解正在推动生物疗法的创新。 2020 年至 2024 年间，美国食品药物管理局(FDA)核准了18 种用于治疗癌症的新型生物疗法。根据欧洲药品管理局的报告，2021 年至 2023 年间，癌症生物疗法的临床试验将增加 35%。这些发展正在带来更有效、更有针对性且副作用更少的治疗方法。 2024 年 3 月，百时美施贵宝推出了一种用于治疗固体癌的突破性 CAR-T 细胞疗法，拓展了这种生物疗法的应用范围。 2024 年 5 月，诺华宣布针对多发性骨髓瘤的双特异性抗体在 III 期临床试验中取得成功，显示无恶化生存期显着改善。

缺乏获得癌症生物疗法的机会或可用性是否会限制其采用？

癌症生物疗法市场发展的一个重大限制是高成本。单株抗体和嵌合抗原受体-T细胞疗法等生物疗法的开发、生产和管理通常成本高。这些成本包括复杂的生产工艺，以及需要由训练有素的医疗保健专业人员进行专业操作和管理。这种经济负担可能会限制许多患者，尤其是在中低收入国家，获得治疗的机会，这给医疗保健系统和保险公司管理这些先进疗法的高昂成本带来了挑战。

癌症生物疗法的可近性和可用性不足也是一大挑战。由于这些疗法的专业性，它们可能无法在所有地区广泛普及，尤其是在偏远和欠发达地区。对先进医疗基础设施（包括专业设施和训练有素的医护人员）的需求进一步限制了生物疗法的普及。此外，监管核准和市场进入障碍可能会延迟新治疗方法的普及，影响这些治疗方法及时送达有需要的患者。

癌症生物疗法可能引起严重的副作用，例如细胞激素释放症候群 (CRS) 和意外的免疫反应。这些副作用需要密切监测，并使治疗通讯协定变得复杂，这对临床医生平衡疗效和安全性提出了挑战。严重的副作用可能会使患者虚弱无力，并给实施生物疗法的医护人员带来额外的挑战。

Increasing global prevalence of cancer boosts demand for innovative treatment options is propelling the adoption of cancer biological therapy. The shift towards personalized medicine, focusing on treatments tailored to individual genetic profiles is driving the market size surpass USD 93.74 Billion valued in 2024 to reach a valuation of around USD 153.35 Billion by 2032.

In addition to this, clinical success and improved patient outcomes with biological therapies are spurring up the adoption of cancer biological therapy. Increased government funding and favorable policies for cancer research and treatment is enabling the market to grow at a CAGR of 7% from 2026 to 2032.

Cancer Biological Therapy Market: Definition/ Overview

Cancer biological therapy, also known as biotherapy or immunotherapy, involves the use of living organisms, substances derived from living organisms, or synthetic versions of such substances to treat cancer. These therapies work by enhancing the body's natural defenses to fight cancer or by targeting specific molecules involved in cancer growth and progression. Examples of biological therapies include monoclonal antibodies, cancer vaccines, and cell-based therapies.

Cancer biological therapies are used to treat various types of cancer, often in combination with other treatments such as chemotherapy, radiation, and surgery. They are particularly effective in targeting specific cancer cells while minimizing damage to normal cells. Monoclonal antibodies can be used to block cancer cell growth, mark cancer cells for destruction by the immune system, or deliver radiation or chemotherapy directly to cancer cells. Cancer vaccines aim to stimulate the immune system to attack cancer cells, and cell-based therapies, such as CAR T-cell therapy, involve modifying a patient's own immune cells to target cancer more effectively.

How will Rising Global Cancer Prevalence Increase Adoption of Cancer Biological Therapy?

The rising global cancer prevalence is a primary driver of the cancer biological therapy market. According to the World Health Organization, cancer cases are projected to increase by 60% by 2040 from 2020 levels. The U.S. National Cancer Institute reported that approximately 39.5% of people will be diagnosed with cancer at some point in their lives. This increasing burden has led to greater demand for effective and targeted treatments like biological therapies. In response to this trend, Merck announced in February 2024 the expansion of its immuno-oncology pipeline, focusing on novel checkpoint inhibitors. Similarly, Roche introduced a new personalized cancer vaccine platform in April 2024, combining mRNA technology with their established biological therapies.

Advancements in biotechnology and a deeper understanding of cancer biology are fueling innovation in biological therapies. The U.S. Food and Drug Administration (FDA) approved 18 new biological therapies for cancer treatment between 2020 and 2024. A report from the European Medicines Agency showed a 35% increase in biological therapy clinical trials for cancer from 2021 to 2023. These developments are leading to more effective and targeted treatments with fewer side effects. In March 2024, Bristol Myers Squibb unveiled a groundbreaking CAR-T cell therapy for solid tumors, expanding the application of this biological approach. Novartis announced in May 2024 the successful phase III trial results for a bispecific antibody targeting multiple myeloma, demonstrating significant improvements in progression-free survival.

Will Lack of Accessibility and Availability of Cancer Biological Therapy Restrain Its Application?

One of the significant restraints in the cancer biological therapy market is the high cost associated with these treatments. Biological therapies, such as monoclonal antibodies and CAR T-cell therapy, are often expensive to develop, produce, and administer. The costs include not only the complex manufacturing processes but also the need for specialized handling and administration by trained healthcare professionals. This financial burden can limit accessibility for many patients, particularly in low- and middle-income countries, and poses a challenge for healthcare systems and insurance providers in managing the high expenses associated with these advanced treatments.

Lack of accessibility and availability of cancer biological therapies are also major challenges. Due to the specialized nature of these treatments, they may not be widely available in all regions, particularly in remote or underdeveloped areas. The need for sophisticated healthcare infrastructure, including specialized facilities and trained personnel, further restricts the widespread adoption of biological therapies. Additionally, regulatory approvals and market entry barriers can delay the availability of new treatments, impacting the timely delivery of these therapies to patients in need.

Cancer biological therapies can cause significant adverse effects and unintended immune responses, such as cytokine release syndrome (CRS). These side effects require careful monitoring and complicate treatment protocols, making it challenging for clinicians to balance efficacy and safety. Severe side effects can deter patients and create additional challenges for healthcare providers in managing biological treatments.

Category-Wise Acumens

Will Rise in Adoption of Monoclonal Antibodies (mAbs) Drive Cancer Biological Therapy Market?

Monoclonal antibodies (mAbs) is emerging as the leading segment in the cancer biological therapy market. According to the FDA, mAbs accounted for 35% of all cancer biological therapy approvals between 2020 and 2024. The National Cancer Institute reported that mAb therapies were used in 40% of cancer treatment regimens in the U.S. by 2023. This dominance is attributed to their high specificity and efficacy in targeting cancer cells. In February 2024, Roche announced the successful phase III trial results for a novel bispecific antibody targeting both HER2 and PD-1 in breast cancer patients. Similarly, Merck launched an advanced mAb therapy in April 2024, demonstrating improved overall survival rates in lung cancer patients.

The versatility of monoclonal antibodies in combination therapies is driving their market growth. The American Society of Clinical Oncology reported a 28% increase in clinical trials involving mAb combination therapies from 2021 to 2023. The European Medicines Agency approved 15 new mAb-based combination treatments between 2020 and 2024. This trend reflects the growing recognition of mAbs' potential to enhance treatment efficacy when used with other therapies. In March 2024, Bristol Myers Squibb introduced a groundbreaking triple combination therapy featuring two mAbs and a small molecule inhibitor for advanced melanoma. AstraZeneca partnered with a leading biotech firm in May 2024 to develop next-generation antibody-drug conjugates for multiple cancer types.

Which Factors Enhance the Use of Cancer Biological Therapy in Hospitals?

Hospitals is expected to emerge as the primary distribution channel for cancer biological therapies. According to the American Hospital Association, 72% of all cancer biological treatments were administered in hospital settings in 2023. The Centers for Medicare & Medicaid Services reported that hospital outpatient departments accounted for 65% of cancer biological therapy claims in 2024. This dominance is attributed to the complex nature of these treatments and the need for specialized care. In February 2024, the Mayo Clinic announced the expansion of its cancer biological therapy units across all major branches. Similarly, Cleveland Clinic partnered with Roche in April 2024 to establish advanced biological therapy infusion centers in its hospitals.

The rise of hospital-based cancer centers is fueling the growth of biological therapy administration. The National Cancer Institute reported a 30% increase in NCI-designated cancer centers from 2020 to 2024. A survey by the American Society of Clinical Oncology found that 80% of oncologists preferred hospital settings for administering complex biological therapies in 2023. This trend reflects the need for comprehensive care and immediate access to emergency services. In March 2024, MD Anderson Cancer Center unveiled a state-of-the-art biological therapy wing, featuring personalized treatment suites. NewYork-Presbyterian Hospital launched an integrated immunotherapy program in May 2024, centralizing all biological therapy services.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure in North America Mature Cancer Biological Therapy Market?

North America leads the global cancer biological therapy market due to advanced healthcare infrastructure and high adoption rates. According to the National Cancer Institute, biological therapies accounted for 35% of all cancer treatments in the U.S. by 2023. The Canadian Cancer Society reported a 28% increase in biological therapy usage from 2020 to 2024. This dominance is fueled by substantial research funding and a robust biotechnology industry. In February 2024, the U.S. FDA approved a record number of 12 new cancer biological therapies. Merck, a key player, announced in April 2024 a USD 2 Billion investment to expand its biological therapy production facilities across North America.

The region's strong reimbursement policies and insurance coverage drive market growth. The Centers for Medicare & Medicaid Services reported that spending on cancer biological therapies increased by 40% between 2020 and 2024. A study by the American Cancer Society found that 85% of cancer patients had access to biological therapies through insurance in 2023. This financial support enhances patient access to advanced treatments. In March 2024, UnitedHealth Group expanded its coverage for CAR-T cell therapies, benefiting thousands of cancer patients. Roche partnered with major U.S. insurers in May 2024 to introduce innovative payment models for its portfolio of biological cancer treatments.

North America's leadership in clinical trials and personalized medicine boosts its market position. The NIH Clinical Trials database showed that 60% of global cancer biological therapy trials were conducted in North America in 2023. Health Canada reported a 25% increase in precision medicine approvals for cancer from 2021 to 2024. This focus on innovation drives the development of more effective therapies. In January 2024, Gilead Sciences launched a groundbreaking personalized neoantigen therapy in the U.S. market. Bristol Myers Squibb announced in June 2024 the successful completion of the largest pan-cancer immunotherapy trial to date, conducted across multiple North American centers.

Will Increasing Cancer Prevalence Enhance Adoption of Cancer Biological Therapy in Asia Pacific?

The Asia Pacific region is experiencing rapid growth in the cancer biological therapy market due to increasing cancer prevalence and improving healthcare infrastructure. According to the World Health Organization, cancer cases in Asia are projected to increase by 35% from 2020 to 2030. China's National Cancer Center reported a 25% rise in biological therapy adoption from 2021 to 2023. This growth is driven by government initiatives and rising healthcare expenditure. In February 2024, the Indian Council of Medical Research announced a $500 million investment in cancer biological therapy research. Japan's Ministry of Health approved 8 new cancer biological therapies in 2023, marking a 40% increase from the previous year.

Expansion of local biopharmaceutical companies and partnerships with global players are fueling market growth. The China National Medical Products Administration reported a 30% increase in domestic cancer biological therapy approvals between 2020 and 2024. South Korea's Ministry of Food and Drug Safety noted a 45% growth in biological therapy clinical trials from 2022 to 2024. These developments are enhancing the region's capacity for advanced cancer treatments. In March 2024, BeiGene partnered with Novartis to expand its biological therapy portfolio across Asia. Singapore-based Tessa Therapeutics raised $200 million in April 2024 to advance its CAR-T cell therapy pipeline for solid tumors. At the forefront, the availability of local vendors offering competitive pricing cloud-based solutions increase the accessibility and availability of Cancer Biological Therapy to businesses of all sizes, driving wider adoption.

Competitive Landscape

The cancer biological therapy market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the cancer biological therapy market include:

Bristol-Myers Squibb
Merck & Co., Inc.
Roche Holding AG
Novartis International AG
AstraZeneca
Pfizer, Inc.
Amgen, Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Johnson & Johnson
Sanofi S.A.
Celgene Corporation (a subsidiary of Bristol-Myers Squibb)
Gilead Sciences, Inc.
AbbVie, Inc.
Biogen, Inc.
Takeda Pharmaceutical Company Limited
Regeneron Pharmaceuticals, Inc.
Seagen, Inc.
Incyte Corporation
Adaptimmune Therapeutics plc.

Latest Developments

In September 2023, Novartis received FDA approval for a next-generation targeted therapy for breast cancer, marking a significant advancement in precision medicine and biological treatments.
In August 2023, AstraZeneca announced a collaboration with a leading research institute to explore the use of gene editing technologies in developing new biological therapies for lung cancer.

1. Introduction

Market Definition
Market Segmentation
Research Methodology

2. Executive Summary

Key Findings
Market Overview
Market Highlights

3. Market Overview

Market Size and Growth Potential
Market Trends
Market Drivers
Market Restraints
Market Opportunities
Porter's Five Forces Analysis

4. Cancer Biological Therapy Market, By Type of Therapy

Monoclonal Antibodies
Cancer Vaccines
Cytokines
Gene Therapy
Targeted Therapy
Others

5. Cancer Biological Therapy Market, By Cancer Type

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Leukemia
Lymphoma
Others

6. Cancer Biological Therapy Market, By End User

Hospitals
Cancer Treatment Centers
Clinics
Ambulatory Surgical Centers
Others

7. Regional Analysis

North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Asia-Pacific
China
Japan
India
Australia
Latin America
Brazil
Argentina
Chile
Middle East and Africa
South Africa
Saudi Arabia
UAE

8. Market Dynamics

Market Drivers
Market Restraints
Market Opportunities
Impact of COVID-19 on the Market

9. Competitive Landscape

Key Players
Market Share Analysis

10. Company Profiles

Amgen
F. Hoffmann-La Roche
Merck Group
Eli Lilly and Company
GSK (GlaxoSmithKline)
Bristol Myers Squibb
Novartis
Celgene (acquired by Bristol Myers Squibb)
Spectrum Pharmaceuticals
AbbVie
AstraZeneca
Astellas
International

11. Market Outlook and Opportunities

Emerging Technologies
Future Market Trends
Investment Opportunities

12. Appendix

List of Abbreviations
Sources and References

02-2729-4219

+886-2-2729-4219

License/价格

2026 年至 2032 年癌症生物治疗市场（按治疗类型、癌症类型、最终用户和地区划分）

Cancer Biological Therapy Market By Type of Therapy (Monoclonal Antibodies, Cancer Vaccines), Cancer Type (Breast Cancer, Lung Cancer), End-User (Hospitals Cancer Treatment Centers), & Region for 2026-2032

癌症生物治疗市场评估-2026-2032

全球癌症发生率的不断上升将如何导致癌症生物疗法的应用增加？

缺乏获得癌症生物疗法的机会或可用性是否会限制其采用？

目录

第一章 引言

第二章执行摘要

第三章市场概述

4. 癌症生物治疗市场（依治疗类型）

第五章 癌症生物治疗市场（依癌症类型）

第六章 癌症生物治疗市场（依最终使用者）

第七章区域分析

第八章市场动态

第九章 竞争态势

第十章 公司简介

第十一章 市场展望与机会

第十二章 附录

Cancer Biological Therapy Market Valuation - 2026-2032